The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: A systematic review

European Journal of Cancer

Volumn 50, Issue 14, 2014, Pages 2432-2448

  Dirven, Linda ^a   Taphoorn, Martin J B ^a,b   Reijneveld, Jaap C ^a,c   Blazeby, Jane ^d   Jacobs, Marc ^e   Pusic, Andrea ^f   Sala, Edoardo La ^g   Stupp, Roger ^h   Fayers, Peter ^i,j   Efficace, Fabio ^g  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g Italian Group for Adult Hematologic Diseases (GIMEMA)   (Italy)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ UNIVERSITY OF ABERDEEN   (United Kingdom)

^j NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

more..

Author keywords

Brain tumour; Clinical decision making; Clinical trial; Patient reported outcome; Quality of life

Indexed keywords

BRAIN TUMOR; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CLINICAL DECISION MAKING; DEMOGRAPHY; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; PATIENT REPORTED OUTCOME; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; AGED; BRAIN NEOPLASMS; FEMALE; MALE; MIDDLE AGED; PROCEDURES; SELF REPORT; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELF REPORT; SURVIVAL RATE;

EID: 84922268466     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.06.016     Document Type: Review

References (48)

1. Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2001;2:552-60.
2. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 2013;15(Suppl. 2):ii1-ii56.
3. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet 2012;379:1984-96.
4. Aaronson NK, Taphoorn MJ, Heimans JJ, Postma TJ, Gundy CM, Beute GN, et al. Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol 2011;29:4430-5.
5. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol 2012;13:916-26.
6. Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, et al. Health-related quality of life in patients with glioblastoma: A randomised controlled trial. Lancet Oncol 2005;6:937-44.
7. Taphoorn MJ, van den Bent MJ, Mauer ME, Coens C, Delattre JY, Brandes AA, et al. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol 2007;25:5723-30.
8. US Department of Health and Human Services Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims [Internet]; 2009 [cited 12 May 2014]. Available from: .
9. Aaronson NK. Quality of life: what is it? How should it be measured?. Oncology (Williston Park) 1988;2:69-76.
10. Efficace F, Bottomley A. Health related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients. Eur J Cancer 2002;38: 1824-31.
11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 2009;62:1006-12.
12. Efficace F, Feuerstein M, Fayers P, Cafaro V, Eastham J, Pusic A. Patient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision making. Eur Urol 2013;Oct 30 [S0302-2838(13)01090-7].
13. Brundage M, Blazeby J, Revicki D, Bass B, de Vet H, Duffy H, et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res 2013;22:1161-75.
14. Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D'haese S, et al. Beyond the development of health-related quality-of-life (HRQOL) measures: A checklist for evaluating HRQOL outcomes in cancer clinical trials - does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 2003;21:3502-11.
15. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
16. Mirimanoff RO, Gorlia T, Mason W, van den Bent MJ, Kortmann RD, Fisher B, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006;24:2563-9.
17. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
18. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
19. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715-22.
20. Stupp R, Tonn JC, Brada M, Pentheroudakis G. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl. 5):v190-3.
21. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31: 344-50.
22. Calvert M, Brundage M, Jacobsen PB, Schunemann HJ, Efficace F. The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice. Health Qual Life Outcomes 2013;11:184.
23. Zikos E, Ghislain I, Coens C, Ediebah DE, Sloan E, Quinten C, et al. Health-related quality of life in small-cell lung cancer: A systematic review on reporting of methods and clinical issues in randomised controlled trials. Lancet Oncol 2014;15:e78-e89.
24. Dirven L, Reijneveld JC, Aaronson NK, Bottomley A, Uitdehaag BM, Taphoorn MJ. Health-related quality of life in patients with brain tumors: limitations and additional outcome measures. Curr Neurol Neurosci Rep 2013;13:359.
25. Walker M, Brown J, Brown K, Gregor A, Whittle IR, Grant R. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. J Neurooncol 2003;63:179-86.
26. Vordermark D. Avoiding bias in the prospective evaluation of patients with brain metastases. J Clin Oncol 2007;25:4023-5.
27. Walther B, Hossin S, Townend J, Abernethy N, Parker D, Jeffries D. Comparison of electronic data capture (EDC) with the standard data capture method for clinical trial data. PLoS One 2011;6:e25348.
28. Maringwa J, Quinten C, King M, Ringash J, Osoba D, Coens C, et al. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol 2011;22:2107-12.
29. Mauer ME, Bottomley A, Taphoorn MJ. Evaluating healthrelated quality of life and symptom burden in brain tumour patients: instruments for use in experimental trials and clinical practice. Curr Opin Neurol 2008;21:745-53.
30. Reijneveld JC, Klein M, Taphoorn MJ, Postma TJ, Heimans JJ. Improved, personalized treatment of glioma necessitates longterm follow-up of cognitive functioning. Pharmacogenomics 2012;13:1667-9.
31. de Haes J, Curran D, Young T, Bottomley A, Flechtner H, Aaronson N, et al. Quality of life evaluation in oncological clinical trials - The EORTC model. The EORTC Quality of Life Study Group. Eur J Cancer 2000;36:821-5.
32. Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, et al. Net clinical benefit analysis of radiation therapy oncology group 0525: A phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol 2013;31:4076-84.
33. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709-22.
34. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. J Clin Oncol 2013;31:4085-91.
35. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:699-708.
36. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension. JAMA 2013;309:814-22.
37. NCCN Clinical Practice Guideline in Oncology; Central Nervous SystemCancers [Internet]; 2014 [citedMay 12 2014].Available from: http://www.nccn.org/professionals/physician-gls/pdf/cns.pdf.
38. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28:1168-74.
39. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. Eur J Cancer 2012;48:2192-202.
40. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004;60:853-60.
41. Levin VA, Phuphanich S, Yung WK, Forsyth PA, Maestro RD, Perry JR, et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 2006;78:295-302.
42. Henriksson R, Malmstrom A, Bergstrom P, Bergh G, Trojanowski T, Andreasson L, et al. High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. J Neurooncol 2006;78:321-6.
43. Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial. J Clin Oncol 2004;22:1583-8.
44. Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007;356:1527-35.
45. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26:5610-7.
46. Kocher M, Frommolt P, Borberg SK, Ruhl U, Steingraber M, Niewald M, et al. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlenther Onkol 2008;184:572-9.
47. Grabenbauer GG, Gerber KD, Ganslandt O, Richter A, Klautke G, Birkmann J, et al. Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2009;75:164-9.
48. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13:707-15.